Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
PHASE2
International multi-center open-label randomized clinical trial of efficacy...
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
PHASE3
This is a randomized, multicenter, double-blind placebo-controlled phase 3 ...
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
PHASE2
This is a multicenter, open-label, single-arm study of efficacy, safety and...
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)
PHASE3
This is a randomized, multicenter, double-blind, Phase 3 study of efficacy ...
Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
PHASE2
This is a multicenter randomized double-blind placebo-controlled phase II c...
Status
Unknown
Location
State Institution "N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology"
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
PHASE3
The aim of study is to investigate the efficacy, safety, immunogenicity, ph...